Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on May 11, 2005
J Am Soc Nephrol 16: 2225-2233, 2005
© 2005 American Society of Nephrology
doi: 10.1681/ASN.2005020175

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2005020175v1
16/7/2225    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Braun, M. C.
Right arrow Articles by Strife, C. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Braun, M. C.
Right arrow Articles by Strife, C. F.

Clinical Transplantation

Recurrence of Membranoproliferative Glomerulonephritis Type II in Renal Allografts: The North American Pediatric Renal Transplant Cooperative Study Experience

Michael C. Braun*, Don M. Stablein{dagger}, Lorraine A. Hamiwka{ddagger}, Lorraine Bell§, Sharon M. Bartosh|| and C. Frederic Strife

* The Brown Foundation Institute of Molecular Medicine and the Department of Pediatrics, Division of Pediatric Nephrology and Hypertension, University of Texas Health Science Center at Houston, Houston, Texas; {dagger} The EMMES Corporation, Rockville, Maryland; {ddagger} Division of Pediatric Nephrology, Alberta Children’s Hospital University of Calgary, Calgary, Alberta, Canada; § Montreal Children’s Hospital, McGill University Heath Centre, Department of Pediatrics, Division of Pediatric Nephrology, Montreal, Quebec, Canada; || Department of Pediatrics, University of Wisconsin, University of Wisconsin Children’s Hospital, Madison, Wisconsin; and Department of Pediatrics, Division of Nephrology and Hypertension, University of Cincinnati College of Medicine, and The Children’s Hospital Research Foundation, Cincinnati, Ohio

Address correspondence to: Dr. Michael C. Braun, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, 2121 W. Holcombe Boulevard, Houston, TX 77030. Phone: 713-500-2438; Fax: 713-500-2424; E-mail: michael.c.braun{at}uth.tmc.edu

Received for publication February 16, 2005. Accepted for publication March 28, 2005.

Membranoproliferative glomerulonephritis type II (MPGN II) is an uncommon form of complement-dependent acquired renal disease. Although it has been recognized since the 1970s that MPGN II recurs almost universally in renal transplants, data regarding the long-term consequences of disease recurrence are limited. Therefore, a retrospective comparative analysis of 75 patients with MPGN II contained in the North American Pediatric Renal Transplant Cooperative Study transplantation database was performed. Five-year graft survival for patients with MPGN II was significantly worse (50.0 ± 7.5%) compared with the database as a whole (74.3 ± 0.6%; P < 0.001). Living related donor organs had a significantly better 5-yr survival (65.9 ± 10.7%) compared with cadaveric donor organs (34.1 ± 9.8%; P = 0.004). The primary cause of graft failure in 11 (14.7%) patients was recurrent disease. Supplemental surveys were obtained on 29 (38%) of 75 patients. Analysis of these data indicated that recurrent disease occurred in 12 (67%) of the 18 patients with posttransplantation biopsies. Although there was no correlation between pretransplantation presentation, pre- or posttransplantation C3 levels, and either disease recurrence or graft failure, there was a strong association between heavy proteinuria and disease recurrence. The presence of glomerular crescents in allograft biopsies had a significant negative correlation with graft survival. At last follow-up, patients with recurrent disease had significantly higher serum creatinine and qualitatively more proteinuria than patients without biopsy-proven disease. These data indicate that recurrent MPGN II has a significant negative impact on renal allograft function and survival.




This article has been cited by other articles:


Home page
CJASNHome page
W. A. Golgert, G. B. Appel, and S. Hariharan
Recurrent Glomerulonephritis after Renal Transplantation: An Unsolved Problem
Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 800 - 807.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
R. J.H. Smith, J. Alexander, P. N. Barlow, M. Botto, T. L. Cassavant, H. T. Cook, S. R. de Cordoba, G. S. Hageman, T. S. Jokiranta, W. J. Kimberling, et al.
New Approaches to the Treatment of Dense Deposit Disease
J. Am. Soc. Nephrol., September 1, 2007; 18(9): 2447 - 2456.
[Abstract] [Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP